Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Lipids are insoluble in water and therefore cholesterol and triglycerides need to be
transported in association with proteins (ie, lipoproteins) in the bloodstream. Lipoproteins …

Background Lipoprotein (a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …

Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

Importance Lipoprotein (a)(Lp [a]) is associated with atherosclerotic disease and aortic
stenosis. Lp (a) forms by bonding between apolipoprotein (a)(apo [a]) and apo B 100 …

The substantial investments in human genetics and genomics made over the past three
decades were anticipated to result in many innovative therapies. Here we investigate the …

Background Data support lipoprotein (a)(Lp [Lp (a)]) being a risk factor for atherosclerotic
cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that …

Cardiovascular-kidney-metabolic (CKM) syndrome is a novel construct recently defined by
the American Heart Association in response to the high prevalence of metabolic and kidney …

This study reviews ancestral differences in the genetics of the LPA gene, risk categories of
elevated lipoprotein (a)[Lp (a)] as defined by guidelines, ancestry-specific Lp (a) risk …

Abstract Lipoprotein (a)[Lp (a)] is a source of residual risk in patients with atherosclerotic
cardiovascular disease (ASCVD). Clinical trials of fully human monoclonal antibodies …